HOW TO GET THE MOST OF YOUR ALPHA-STIM

1 Illustrated owner's manual
2 Animated protocols on DVD
3 Step-by-step printed protocols

If you have any additional questions, please call us at 800-684-9343 or send us an email at info@alleviahealth.com . Remember, your Alpha-Stim device comes with FREE technical support. We will be happy to talk with you. Yours in health, Allevia Health Support Team.

OUR OFFICE HOURS

Mon-Fri 9:00AM - 5:00PM PST
Tel: 1-800-684-9343

Efficacy Surveys

Alpha-Stim CES Postmarketing Surveys

Two postmarking surveys of the efficacy of the Alpha-Stim® technology were conducted for the FDA in 1995 and 1998 by the manufacturer of Alpha-Stim®, Electromedical Products International, Inc. The following are treatment outcomes with 500 cases (65% female, 5 to 92 years old) reported by 44 physicians. Outpatients comprised 85% (n=423) of all patients, 41% of patients (n=194) satisfactorily completed their CES treatment, while 207 patients (43%) were still receiving treatment at the time of the survey.

The vast majority of patients (94.4%; n=472) reported no adverse side effects of CES therapy, 6 patients (1.2%) reported vertigo, 3 (0.6%) skin irritation, 2 (0.4%) nausea, and 1 (0.2%) each reported anger, a metallic taste in the mouth, a heavy feeling, or intensified tinnitus. These side effects are generally limited and disappear once the intensity of the current is reduced.

The degree of improvement in the patient’s symptoms was recorded for multiple indications for which CES was prescribed. Similar to pharmaceutical studies, a level of improvement of at least 25% was considered clinically relevant. See Kirsch (2002) for more information.

 

Condition N Worse No Change Slight
<24%
Fair
25-49%
Moderate
50-74%
Marked
75-99%
Complete
100%
Clinically
Significant
>25%
Anxiety 349 0.00 2.29 4.01 11.17 25.50 51.86 5.16 93.70
Stress 259 0.00 2.32 4.63 14.29 27.03 47.88 3.86 93.05
Insomnia 135 0.00 11.85 8.89 12.59 25.19 33.33 8.15 79.26
Depression 184 0.00 4.35 5.98 16.85 20.65 44.57 7.61 89.67
Pain 286 0.35 1.75 6.99 16.78 26.92 37.76 9.44 90.91
Muscle Tension 259 0.77 2.32 2.32 16.22 29.34 42.86 6.18 94.59

Download results of Alpha-Stim postmarketing surveys

Survey of Alpha-Stim Warranty Cards

Additional support for the efficacy and safety of Alpha-Stim®, and validation of the post-marketing clinical results achieved with this therapy, comes from an analysis of warranty cards completed in 2000. The analysis included 2,500 consecutive survey forms submitted by patients (72% female, 15 to 92 years old, mean age 50 years) with multiple symptoms who have used Alpha-Stim® MET or CES for at least 3 weeks. The length of treatment ranged from 3 weeks to 5 years (average 3.5 months).

None of the patients reported any significant side effects of the therapy even though they were explicitly asked to list them on the warranty card. A level of improvement of at least 25% was considered clinically significant. See Smith (2001) for more information.

Condition N Slight
24%
Fair
25-49%
Moderate
50-74%
Marked
75-100%
Clinically
Significant
>25%
Anxiety (with other) 370 8.92 22.97 32.97 35.14 91.08
Anxiety/Depression 58 5.17 32.76 32.76 29.31 94.83
Stress 123 4.88 24.39 31.71 39.02 95.12
Insomnia 163 6.13 28.83 28.83 36.20 93.87
Depression (alone) 53 13.21 20.75 43.40 22.64 86.79
Depression (with other) 265 10.94 23.02 35.09 30.94 89.06
Chronic Fatigue 50 6.00 60.00 20.00 14.00 94.00
Psychological (All Cases) 723 8.44 24.20 32.78 34.58 91.56
Condition N Slight
<24%
Fair
25-49%
Moderate
50-74%
Marked
75-100%
Clinically
Significant
>25%
Back Pain 403 4.96 27.05 38.96 29.03 95.04
Cervical Pain 265 6.79 26.04 47.17 20.00 93.21
Hip/Leg/Foot Pain 160 3.75 26.88 33.13 36.25 96.25
Shoulder/Arm/Hand Pain 150 8.67 27.33 42.00 22.00 91.33
Carpal Tunnel 25 0.00 20.00 68.00 12.00 100.00
Arthritis Pain 188 5.85 27.13 46.81 20.21 94.15
TMJ Pain 158 10.76 37.97 37.97 13.29 89.24
Myofascial Pain 62 9.68 29.03 29.03 32.26 90.32
Reflex Sympathetic Dystrophy 55 18.18 29.09 34.55 18.18 81.82
Fibromyalgia (alone) 142 9.15 37.32 36.62 16.90 90.85
Fibromyalgia (with other) 363 9.09 36.09 41.87 12.95 90.91
Migraine 118 1.69 41.53 25.42 31.36 98.31
Headaches (all other) 112 17.86 26.79 21.43 33.93 82.14
Pain (all cases) 723 8.44 24.20 32.78 34.58 91.56

Download results of Alpha-Stim warranty card survey

Kirsch, Daniel L. (2002).The Science Behind Cranial Electrotherapy Stimulation, 2nd Edition, Medical Scope Publishing Corporation, Edmonton, Alberta, Canada, 224 pp.
Smith, Ray B. (2001). Is microcurrent stimulation effective in pain management? An additional perspective. American Journal of Pain Management 11(2):62-66.

TOP